Rivus Pharmaceuticals

Rivus Pharmaceuticals is a non-listed biotechnology company focused on developing a new class of medicines designed to address obesity. The company was founded in 2019 and is headquartered in Charlottesville, Virginia in the US. Rivus is advancing a new class of therapies called Controlled Metabolic Accelerators (CMAs) designed to selectively reduce excess fat by leveraging mitochondrial uncoupling. For its lead program HU6, Rivus has completed Phase I studies and a Phase IIa metabolic study. Rivus recently initiated a Phase IIa study in obese patients with heart failure with preserved ejection fraction and plans to initiate a Phase IIb study in obesity, including a subset of patients with type 2 diabetes, in 2023. Rivus is expanding the therapeutic utility of mitochondrial uncoupling with new CMAs targeting a myriad of diseases where preclinical evidence for safe metabolic acceleration is strong and the therapeutic need is substantial.